What You Should Know:

您应该知道：

– Unnatural Products, Inc. (UNP), a biotech company harnessing the power of AI and chemistry to design the next generation of targeted therapeutics, has secured $32M in Series A funding.

–Unnatural Products，Inc.（UNP）是一家利用人工智能和化学的力量设计下一代靶向治疗药物的生物技术公司，已获得3200万美元的a系列资金。

– Led by Merck Global Health Innovation Fund (MGHIF) and TechBio-focused ARTIS Ventures,  the funding will help propel UNP’s innovative platform and expand its reach beyond oncology, tackling a wider range of medical challenges.

–由默克全球健康创新基金（MGHIF）和专注于TechBio的ARTIS Ventures领导，该资金将有助于推动UNP的创新平台，并将其覆盖范围扩展到肿瘤学之外，应对更广泛的医学挑战。

Macrocycles: Nature’s Key to Untapped Drug Targets

大环化合物：自然界未开发药物靶标的关键

Macrocycles, cyclic molecules with unique properties, offer immense potential for tackling previously undruggable targets. They combine the potency and selectivity of antibodies with the oral bioavailability of small molecules, making them ideal for targeting intracellular proteins.

大环化合物是具有独特性质的环状分子，为解决以前不可药用的靶标提供了巨大的潜力。它们将抗体的效力和选择性与小分子的口服生物利用度相结合，使其成为靶向细胞内蛋白质的理想选择。

UNP’s AI-Fueled Platform: Revolutionizing Macrocycle Drug Discovery

UNP的人工智能平台：彻底改变大环药物的发现

UNP leverages a unique platform that combines parallel chemistry with AI-driven target identification and optimization. This enables the rapid development of synthetic macrocycles with the desirable drug-like properties of their natural counterparts.

UNP利用了一个独特的平台，该平台将并行化学与AI驱动的目标识别和优化相结合。这使得合成大环化合物的快速发展具有其天然对应物所需的类似药物的性质。

“This is a pivotal moment for UNP,” says CEO and Co-Founder, Cameron Pye. “With this funding, we will accelerate the development of our platform and expand beyond oncology into new therapeutic areas. Macrocycles have the potential to revolutionize drug development, just like antibodies did in the early 2000s.”.

首席执行官兼联合创始人卡梅伦·佩伊（CameronPye）表示：“这对联合国邮政来说是一个关键时刻。”。“有了这笔资金，我们将加快平台的发展，并将其扩展到肿瘤学以外的新治疗领域。大环化合物有可能彻底改变药物开发，就像21世纪初抗体一样。”。